Why Masimo (MASI) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 4, 2026

Here's Why You Should Add Masimo Stock to Your Portfolio Now

MASI targets 7%-10% revenue growth through 2028, sharp margin expansion and rising cash flow as intelligent monitoring and partnerships gain traction.

Zacks Investment Research • Feb 4, 2026

Owlet vs. Masimo: Which Medical Monitoring Stock Is the Better Buy?

Remote and continuous patient monitoring is moving from a niche capability to a core pillar of modern healthcare, driven by aging populations, staffing shortages, and a push toward data-driven care both inside hospitals and at home. Against this backdrop, Owlet, Inc. OWLT and Masimo Corporation MASI represent two very different ways to invest in the same secular trend.

Zacks Investment Research • Jan 29, 2026

Why Masimo (MASI) is Poised to Beat Earnings Estimates Again

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Jan 27, 2026

Wall Street Analysts Think Masimo (MASI) Could Surge 31.06%: Read This Before Placing a Bet

The consensus price target hints at a 31.1% upside potential for Masimo (MASI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Jan 27, 2026

FMS or MASI: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 26, 2026

Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors.

GlobeNewsWire • Jan 21, 2026

Masimo Stock Declines Despite Solid Preliminary Q4 Revenues

MASI posts strong fourth-quarter and full-year 2025 preliminary results with revenue and EPS above estimates, driven by core healthcare momentum.

Zacks Investment Research • Jan 15, 2026

Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Masimo Announces Select Preliminary 2025 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Quarter 2025 Financial Results:   •   Revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis(1);   •   Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be.

Business Wire • Jan 12, 2026